Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring

2009 ◽  
Vol 5 (9) ◽  
pp. 1023-1038 ◽  
Author(s):  
Patrick Y Muller ◽  
Frank Dieterle
Vaccine ◽  
2021 ◽  
Author(s):  
Ting Yang ◽  
Baofeng Liu ◽  
Lei Yue ◽  
Tianhong Xie ◽  
Hua Li ◽  
...  

2010 ◽  
Vol 19 (2) ◽  
pp. 273-278 ◽  
Author(s):  
Anne E. Hochwalt ◽  
Michaelle B. Jones ◽  
Sandy J. Meyer

1995 ◽  
Vol 5 (S2) ◽  
pp. S85-S88 ◽  
Author(s):  
O. M. Silvay-Mandeau ◽  
C. Meissner ◽  
B. I. Wenzel-Hora

2018 ◽  
Vol 295 ◽  
pp. S236
Author(s):  
C. Turek ◽  
P. Molnar-Pfitzner ◽  
N. Mörbt ◽  
M.B. Müller ◽  
P. Vögele ◽  
...  

2013 ◽  
Vol 27 (8) ◽  
pp. 2203-2212 ◽  
Author(s):  
D.M. Cameron ◽  
D.A. Donahue ◽  
G.-E. Costin ◽  
L.E. Kaufman ◽  
J. Avalos ◽  
...  

2014 ◽  
Vol 210 (1) ◽  
pp. S394
Author(s):  
Hye Heo ◽  
Yelena Kogelman ◽  
Wade Koba ◽  
Linda Jelicks ◽  
Kamalakar Ambadipudi ◽  
...  

1992 ◽  
Vol 20 (3-2) ◽  
pp. 501-505 ◽  
Author(s):  
Dai T. Davies

This short paper will briefly discuss the merits of determining plasma enzyme activities in pre-clinical safety evaluation. Emphasis is placed on the value of selecting the appropriate enzymes and collecting blood samples at the appropriate times during the study, so as to gain the maximum amount of diagnostic information. Examples of actual results will be cited to illustrate some of the points. These examples are drawn from the 2 commonly used toxicology species—the laboratory white rat and the beagle—and serve to demonstrate the importance of enzymology in monitoring the progress or resolution of an adverse drug effect.


2006 ◽  
Vol 15 (4) ◽  
pp. 226-229 ◽  
Author(s):  
Tetsuya Kodama ◽  
Atsuko Aoi ◽  
Georges Vassaux ◽  
Shiro Mori ◽  
Hidehiro Morikawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document